

ARiA VIII SYMPOSIUM

Advances and Research
in ATTR Amyloidosis

Striving to improve outcomes for your patients with ATTR amyloidosis

📅 22nd – 23rd February 2019

📍 Amsterdam, The Netherlands

DAY 1 — Friday 22nd February 2019

AGENDA

Welcome and introduction

09:00	Meeting open
09:05	Welcome to ARiA VIII
09:20	Pfizer's commitment to ATTR amyloidosis: Helping patients reclaim their lives and future

Session 1: "Back to basics"

09:30	The role of transthyretin in health and disease
09:50	From genes to disease: Navigating the variance landscape
10:10	Back to the future: The latest research in ATTR amyloidosis
10:50	<i>Coffee break & poster viewing</i>

Session 2: Workshops – Doing the best for our patients: Experiences and learnings from a Centre of Excellence

Please attend both sessions within your allocated Workshop, detailed in your tablet

Workshop A: Experience with ATTR amyloid polyneuropathy

Workshop B: Experience with ATTR amyloid cardiomyopathy

11:30	Session 1
12:15	Session 2
13:00	<i>Lunch</i>

Session 3: The value of real-world and long-term data in clinical decision making

14:00	Tafamidis for ATTR amyloid polyneuropathy
14:20	Can we predict response to treatment?
14:40	THAOS: What have we recently learned from registry data?

Session 4: Delegate poster presentations


15:00	Presentations from selected poster authors
15:40	<i>Working coffee break: Poster presentations</i>

Session 5: From the patients' perspective

16:10	Putting the patient at the heart of what we do
-------	--

Day 1 close

16:45	Close of Day 1
-------	----------------



ARiA VIII SYMPOSIUM

Advances and Research
in ATTR Amyloidosis

Striving to improve outcomes for your patients with ATTR amyloidosis

📅 22nd – 23rd February 2019

📍 Amsterdam, The Netherlands

DAY 2 — Saturday 23rd February 2019

AGENDA

Welcome to Day 2

09:00 Welcome to Day 2

Session 6: How do we define disease onset and monitor disease progression?

09:10 Monitoring carriers of a *TTR* mutation

09:30 Monitoring disease progression in patients with ATTR amyloidosis

Session 7: Workshops – Best practice in the clinical setting

Please attend both sessions within your allocated Workshop, detailed in your tablet

Workshop A: Putting consensus papers into the context of everyday practice

1. Monitoring carriers of a *TTR* mutation: Clinical cases
2. Monitoring disease progression in patients with ATTR amyloidosis: Clinical cases

Workshop B: Diagnosing and managing ATTR amyloid cardiomyopathy

1. Scintigraphy: Getting the protocol and analysis right
2. Best practice in patient management once a diagnosis of ATTR amyloid cardiomyopathy has been established

09:50 Session 1

10:20 Session 2

10:50 *Coffee break & poster viewing*

Session 8: The diagnosis debate

11:20 Do biopsy and histology still play a role in diagnosis of ATTR amyloidosis in 2019?

Session 9: Looking to the future

12:00 The future of research in rare diseases

12:20 Genetic testing: Value and modern approaches

12:40 Key updates in the field of ATTR amyloidosis: What is the impact to our practice?

Key learnings and meeting summary

13:00 Poster award winners

13:05 Closing remarks